Our news
NeoPhore appoints Dr John Haurum as Non-Executive Director
Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…
NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme
Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…
NeoPhore Appoints Jeffrey Roix as Chief Executive Officer
NeoPhore Limited, a cancer immuno-oncology company, today announced the appointment of Jeffrey Roix as Chief Executive Officer, with immediate…
NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board
Company attracts world-leading researchers who discovered the role of mismatch repair biology in cancer and cancer immunotherapy NeoPhore Limited, a…
Other news
‘Big place’ for small-molecule booster drugs in cancer immunotherapy, says NeoPhore CEO
APM Health: Interview with CEO, Jeff Roix
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…
UK’s NeoPhore pioneers new approach to cancer immunotherapy
Pharmaphorum: Newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that…